Loading...
XNASORIC
Market cap561mUSD
Jan 10, Last price  
7.96USD
1D
-6.35%
1Q
-14.68%
IPO
-69.46%
Name

Oric Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:ORIC chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
21.87%
Rev. gr., 5y
%
Revenues
0k
Net income
-101m
L+10.08%
-22,029,000-21,363,000-25,486,000-97,270,000-77,677,000-91,477,000-100,697,000
CFO
-86m
L+14.03%
-20,832,000-20,683,000-23,533,000-45,268,000-59,541,000-75,143,000-85,688,000
Earnings
Mar 10, 2025

Profile

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
URL
http://oricpharma.com/
IPO date
Apr 24, 2020
Employees
89
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
111,812
87,733
Unusual Expense (Income)
NOPBT
(111,812)
(87,733)
NOPBT Margin
Operating Taxes
2,355
Tax Rate
NOPAT
(111,812)
(90,088)
Net income
(100,697)
10.08%
(91,477)
17.77%
Dividends
Dividend yield
Proceeds from repurchase of equity
85,000
26,169
BB yield
-17.96%
-11.20%
Debt
Debt current
2,752
2,659
Long-term debt
2,752
2,668
Deferred revenue
(9)
Other long-term liabilities
7,461
6,258
Net debt
(229,535)
(222,896)
Cash flow
Cash from operating activities
(85,688)
(75,143)
CAPEX
(849)
(2,078)
Cash from investing activities
(43,403)
(109,248)
Cash from financing activities
85,658
25,624
FCF
(120,565)
(90,928)
Balance
Cash
208,187
206,272
Long term investments
26,852
21,951
Excess cash
235,039
228,223
Stockholders' equity
(434,663)
(335,516)
Invested Capital
668,964
566,784
ROIC
ROCE
EV
Common stock shares outstanding
51,451
39,655
Price
9.20
56.20%
5.89
-59.93%
Market cap
473,348
102.66%
233,569
-58.14%
EV
243,813
10,674
EBITDA
(110,780)
(86,767)
EV/EBITDA
Interest
2,645
Interest/NOPBT